Jaguar Health (NASDAQ: JAGX) today announced that the merger of its Italian subsidiary Napo EU S.p.A. and Dragon SPAC S.p.A. has closed.
“We know shareholders and other stakeholders have been eagerly awaiting the completion of all the administrative steps, including Italian governmental approval, required to consummate the merger. I am very pleased to announce that the merger of Dragon SPAC and Napo EU is closed and that the combined entity has retained the name Napo EU S.p.A.,” stated Lisa Conte, Jaguar’s president, and CEO and Napo EU board member.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise.
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.